NCT05652283View on ClinicalTrials.gov

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 6, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

May 1, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

Pamiparib

Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles

DRUG

Surufatinib

Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles

Trial Locations (1)

230001

Anhui Cancer Hospital, Hefei

All Listed Sponsors
lead

Bai-Rong Xia

OTHER